How to Compare Quotes for Hers Cost Without Missing Extra Fees
Normalize every quote to the same three variables before comparing anything: strength, term length, and what the number includes. Most gaps between telehealth quotes come from those three moving independently, not from one provider being cheaper. The fees that get missed are almost always dose escalation, monitoring, shipping, and the price that applies after an introductory term ends.
A quote in this market is not a fixed offer
Retail pricing conditions people to expect a quote to be a price. In direct-pay telehealth it is closer to an entry point. The figure shown before intake is usually conditional on a clinician prescribing at all, on a particular starting strength, on a particular prepaid term, and on a promotional window with an end date. Hers, the women’s brand of Hims and Hers Health, sells across weight, hair, skin, mental health, and sexual health, and a quote pulled from one of those lines has no bearing on another. The first job in any comparison is establishing what each number is a quote for.
The fee categories that sit outside the headline
Dose-dependent pricing is the largest. Injectable weight treatments are titrated upward on a schedule set in approved labeling, so a program that prices by strength has a price ladder rather than a price. Two providers quoting the same opening figure can diverge substantially by month four.
Monitoring is the second. It is not a fee at all in some programs and a real recurring charge in others, depending on which drug is prescribed and whether the program reviews results. Shipping is the third, and it is charged per shipment more often than per plan, so a program that ships every four weeks costs more to receive than one shipping quarterly at the same drug price.
The fourth is the post-promotional rate. An introductory term that reverts to a standard rate is a two-part price, and only the second part matters over a year. The fifth is the cancellation boundary: the last date on which stopping avoids the next charge, which in a prepaid model may not exist at all until the term ends.
| Fee category | How it appears in a quote | Ask this in writing | Why two quotes diverge |
|---|---|---|---|
| Dose escalation | Usually absent | Price at each strength on the ladder | Different starting strengths quoted |
| Monitoring and labs | Listed as included or not mentioned | Required at baseline, at follow-up, or never | Different drugs carry different requirements |
| Shipping | Free on the first order | Per shipment or per term, and how often | Different refill cadence |
| Post-promotional rate | Footnoted | The standard rate and the date it starts | One quote is promotional, the other is not |
| Term commitment | Shown as a low monthly figure | Total paid up front and refund policy | Prepaid term compared to month to month |
| Consultation | Bundled or waived | Charged if no prescription is issued | Different bundling conventions |
The normalization method
Convert every quote to a twelve month total at the maintenance strength, on the term actually being purchased, with monitoring and shipping added. That single conversion removes most of the apparent differences between providers and exposes the real ones. Do it twice for any prepaid offer: once assuming the term completes, and once assuming treatment stops in month three. The second figure is where the surprises live, because the discount that made the offer attractive was consideration for a commitment that did not happen.
Comparing two quotes is really comparing two pricing policies, which is why it pays to read the published terms of the provider behind it rather than the headline figure. Across the field this varies: LillyDirect and NovoCare publish self-pay terms for their own approved products, Ro and Noom price weight programs separately from medication, WeightWatchers Clinic and Found bundle differently again, and FormBlends sets out plan length and medication pricing before the consultation. Any program that answers the strength question in writing can be normalized. One that will not is not comparable to anything.
Questions specific to women’s treatment lines
Some cost questions only arise on the women’s side. If an oral contraceptive is already in use, tirzepatide labeling advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase, which is a real out-of-pocket item that no quote includes. Delayed gastric emptying with these drugs affects the absorption of other oral medications generally, and a systematic review of those interactions is worth reading before assuming the rest of a medicine cabinet is unaffected.
If pregnancy is being planned, the weight line has a hard stop rather than a pause. Semaglutide labeling calls for stopping at least two months before a planned pregnancy because of the long half-life. That is not a cost detail buried in a footnote, it is a reason not to buy a long prepaid term in the first place.
What the price difference on compounded options actually buys
Compounded preparations are frequently the cheapest quote on the table. They are also not FDA-approved, which means the specific preparation has not been reviewed for safety, effectiveness, or manufacturing quality, and compounding operates under a separate set of laws and policies from approved drug manufacturing. A managed care review aimed at prescribers sets out what that distinction means in practice. Treating a compounded quote and an approved-product quote as the same purchase at different prices is the single largest error in this comparison.
None of this normalization works without prices to feed into it, which is why the providers worth comparing are the ones that quote in writing. Beyond the manufacturer self-pay channels, direct-pay names such as Hims and Hers and Henry Meds post their weight terms, and HealthRX publishes pricing for GLP-1 medications at each strength rather than a single opening figure. A quote that can be read at every rung of the ladder converts cleanly to an annual total; one that stops at the first month does not.
Frequently asked questions
What is the minimum information a quote needs to be usable?
The drug and its strength, the term length, whether monitoring and shipping are included, the rate after any introductory period, and the refund position if treatment stops early. A quote missing any of those cannot be converted to an annual figure, which means it cannot be compared to a competing quote at all.
Is a lower monthly figure ever the whole story?
Only for stable treatments with no titration and no monitoring, such as a long-standing topical. For anything titrated, the monthly figure is a snapshot of the cheapest month. Comparing snapshots across providers reliably produces the wrong answer about which program costs less over a year.
How should prepaid discounts be handled in a comparison?
As a conditional price, because that is what they are. Price the term at completion and again at early termination, then decide whether the discount is worth the commitment. A three month prepaid rate set against a month to month rate at another provider is not a like for like comparison.
Do quotes differ between women’s and men’s programs for the same drug?
They can, because the treatment lines differ. Hair and skin prescribing for women often uses different molecules with different monitoring requirements, and the contraception guidance attached to tirzepatide applies only on one side. Those differences change the total even when the headline injectable price looks identical.
Sources
- DailyMed, Zepbound (tirzepatide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- DailyMed, Wegovy (semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. https://pubmed.ncbi.nlm.nih.gov/37940101/
- Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/38273155/
- Navigating compounded semaglutide: what health care providers need to know. https://pubmed.ncbi.nlm.nih.gov/40966636/
- FDA, Human Drug Compounding: Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, BeSafeRx: Your Source for Online Pharmacy Information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
- Definition and diagnostic criteria of clinical obesity. https://pubmed.ncbi.nlm.nih.gov/39824205/